由于短缺、成本和保险问题,美国人在获得减重药品方面面临挑战。 Americans face challenges accessing weight-loss drugs due to shortages, costs, and insurance issues.

由于供应短缺、保险问题和高成本,美国人在获得像Mounjaro和Wegovy这样的减重药物方面面临挑战。 Americans are facing challenges accessing weight-loss drugs like Mounjaro and Wegovy due to supply shortages, insurance issues, and high costs. 这些障碍导致一些人在网上寻找价格更便宜、更复杂的版本,引起对安全和有效性的关切。 These obstacles have led some to seek cheaper, compounded versions online, raising concerns about safety and effectiveness. 药商Eli Lilly和Novo Nordisk报告说,他们的肥胖药物销售严重短缺。 Drugmakers Eli Lilly and Novo Nordisk reported significant sales shortfalls for their obesity drugs. 尽管林业发展局已经解决了一些供应问题,但患者仍难以填写处方。 Although the FDA has addressed some supply issues, patients still struggle to fill prescriptions.